Candice Roth, MSN, RN, CENP, Describes the Evolution of Electronic Treatment Pathways at Levine Cancer Institute


Candice Roth, MSN, RN, CENP, spoke about how the electronic treatment pathways have evolved over time.

At the Association of Community Cancer Centers 48th Annual Meeting and Cancer Center Business Summit, CancerNetwork® spoke with Candice Roth, MSN, RN, CENP, assistant vice president at Levine Cancer Institute in Charlotte, North Carolina, about how measuring success of electronic treatment pathways has evolved from counting the number of clicks to specifically pinpointing how clinicians are using the platform.


First and foremost, it was a new platform several years ago, so just getting providers to use it compared with the way they previously practiced [was difficult]. It was [simply about] just counting the number of clicks initially in terms of metrics. [We were focused on making] sure that our providers were aware that they needed to use this platform and or that it was available for their use. Similarly, any of our nurses can do the same.

In terms of metrics, initially it was very much about how many clicks we had. Then as we progressed, we’ve been able to track clinical trial touchpoint eligibility for patients. We also look at ensuring that we are being consistent and standard by way of how we treat breast cancer, for example. We have all those metrics and all of the behind the scenes [information] that we monitor and present by way of dashboards to all of our providers.

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content